Letrozole Sandoz

Letrozole, the active ingredient in Letrozole Sandoz, is a non‑steroidal aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone receptor‑positive breast cancer in postmenopausal women, both in early‑stage adjuvant and metastatic settings.

GNH USA supplies Letrozole Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring product quality, regulatory compliance and reliable logistics across global markets. Our distribution network adheres to stringent temperature and handling standards to maintain drug integrity.

Letrozole is used in endocrine therapy targeting estrogen‑dependent breast cancer pathways.

- Postmenopausal hormone receptor‑positive breast cancer: reduces tumor growth by lowering estrogen levels. - Adjuvant treatment of early‑stage disease: decreases risk of recurrence after surgery. - Metastatic hormone‑sensitive breast cancer: helps control disease progression in advanced cases.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Fatigue: persistent tiredness affecting daily activities. - Joint and muscle pain: arthralgia or myalgia. - Nausea: upset stomach, sometimes with vomiting. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases or hepatic failure. - Bone fractures: increased risk of osteoporosis‑related breaks. - Pulmonary embolism: blood clot in the lungs, requiring urgent care. - Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty. - QT interval prolongation: potential cardiac arrhythmia.

Before initiating Letrozole, several safety considerations should be reviewed.

- Pregnancy contraindication: drug is category X and must not be used during pregnancy. - Menopausal status: indicated only for postmenopausal women; assess menopausal criteria before use. - Bone health monitoring: evaluate risk of osteoporosis and consider calcium/vitamin D supplementation. - Liver function: perform baseline hepatic tests and monitor periodically. - Drug interaction review: check concomitant medications for CYP2A6 inhibitors or estrogen‑containing therapies. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Letrozole can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors: may increase letrozole plasma concentrations. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Tamoxifen: concurrent use may reduce effectiveness of both agents.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may alter anticoagulant effect; monitor INR. - CYP3A4 inducers (e.g., rifampicin): may lower letrozole exposure. - Antidepressants affecting QT interval: monitor cardiac rhythm.